BR9907883A - Composição de vacina, processo para eliciar uma resposta imune a um antìgeno de vìrus de herpes simplex, e, composição imunogênica - Google Patents

Composição de vacina, processo para eliciar uma resposta imune a um antìgeno de vìrus de herpes simplex, e, composição imunogênica

Info

Publication number
BR9907883A
BR9907883A BR9907883A BR9907883A BR9907883A BR 9907883 A BR9907883 A BR 9907883A BR 9907883 A BR9907883 A BR 9907883A BR 9907883 A BR9907883 A BR 9907883A BR 9907883 A BR9907883 A BR 9907883A
Authority
BR
Brazil
Prior art keywords
immune response
herpes simplex
simplex virus
elicit
virus antigen
Prior art date
Application number
BR9907883A
Other languages
English (en)
Inventor
John H Eldridge
Eric M Mishkin
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of BR9907883A publication Critical patent/BR9907883A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

"COMPOSIçãO DE VACINA, PROCESSO PARA ELICIAR UMA RESPOSTA IMUNE A UM ANTìGENO DE VìRUS DE HERPES SIMPLEX, E, COMPOSIçãO IMUNOGêNICA" Esta invenção pertence a composições de vacina compreendendo uma mistura de antígeno, como um antígeno de vírus de herpes simplex, e a interleucina IL-12, que pode ser adsorvida sobre um mineral em suspensão. Estas composições de vacina modulam a resposta imune protetora para o antígeno.
BR9907883A 1998-02-12 1999-02-10 Composição de vacina, processo para eliciar uma resposta imune a um antìgeno de vìrus de herpes simplex, e, composição imunogênica BR9907883A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7450398P 1998-02-12 1998-02-12
PCT/US1999/002923 WO1999040938A2 (en) 1998-02-12 1999-02-10 Vaccines comprising interleukin-12 and herpes simplex viral antigen

Publications (1)

Publication Number Publication Date
BR9907883A true BR9907883A (pt) 2000-11-14

Family

ID=22119907

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9907883A BR9907883A (pt) 1998-02-12 1999-02-10 Composição de vacina, processo para eliciar uma resposta imune a um antìgeno de vìrus de herpes simplex, e, composição imunogênica

Country Status (15)

Country Link
US (1) US6488936B1 (pt)
EP (1) EP1053017B1 (pt)
JP (1) JP2002502884A (pt)
KR (1) KR100622716B1 (pt)
CN (1) CN1224422C (pt)
AT (1) ATE275421T1 (pt)
AU (1) AU764036B2 (pt)
BR (1) BR9907883A (pt)
CA (1) CA2320041A1 (pt)
DE (1) DE69919984T2 (pt)
DK (1) DK1053017T3 (pt)
ES (1) ES2226338T3 (pt)
IL (1) IL137811A (pt)
PT (1) PT1053017E (pt)
WO (1) WO1999040938A2 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0201220A3 (en) * 1999-05-13 2004-07-28 Wyeth Holdings Corp Madison Adjuvant combination formulations
EP1238086B1 (en) * 1999-12-17 2006-03-08 Wyeth Holdings Corporation Vaccine for enhancing immune responses to herpes simplex virus
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
MXPA03003638A (es) * 2000-10-27 2004-01-26 Immuno Rx Inc Inmunoterapia con vacuna para pacientes inmunosuprimidos.
CZ20031225A3 (cs) * 2000-11-10 2003-10-15 Wyeth Holdings Corporation Adjuvantní kombinované prostředky
US6867000B2 (en) 2000-12-07 2005-03-15 Wyeth Holdings Corporation Method of enhancing immune responses to herpes
JP2004099584A (ja) 2002-05-02 2004-04-02 Keio Gijuku Ｈｓｖを用いた抗腫瘍剤
CN1301749C (zh) * 2005-12-09 2007-02-28 复旦大学 抗单纯疱疹病毒－2感染的多表位dna疫苗及其制备方法
US7790203B2 (en) * 2005-12-13 2010-09-07 Lowder Tom R Composition and regimen for the treatment of herpes simplex virus, herpes zoster, and herpes genitalia epidermal herpetic lesions
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
SI2484375T1 (en) 2006-09-26 2018-08-31 Infectious Disease Research Institute A vaccine composition comprising a synthetic adjuvant
CA3017298C (en) 2009-05-15 2021-09-28 Irx Therapeutics, Inc. Compositions comprising primary cell-derived biologics for enhancing immune responses in patients
WO2010141861A1 (en) 2009-06-05 2010-12-09 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
WO2011056650A2 (en) 2009-10-27 2011-05-12 Michael Zasloff Methods and compositions for treating and preventing viral infections
CN103097543A (zh) 2009-12-08 2013-05-08 伊尔克斯治疗有限公司 逆转朗格汉斯细胞免疫抑制的方法
NZ616304A (en) 2011-04-08 2016-01-29 Immune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
AU2013262691B2 (en) 2012-05-16 2018-12-20 Immune Design Corp. Vaccines for HSV-2
AU2014253791B2 (en) 2013-04-18 2019-05-02 Immune Design Corp. GLA monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022473A1 (en) * 1993-04-01 1994-10-13 University Of Washington Use of interleukin 7 to improve vaccine potency
US5571515A (en) * 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
IL114576A0 (en) * 1994-07-22 1995-11-27 Merck & Co Inc Polynucleotide herpes virus vaccine
GB9422990D0 (en) * 1994-11-15 1995-01-04 Cortecs Ltd Immunogenic compositions
WO1998008947A1 (en) * 1995-12-19 1998-03-05 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Enhancement of dna immunization through the use of cytokines

Also Published As

Publication number Publication date
CN1299287A (zh) 2001-06-13
DE69919984D1 (de) 2004-10-14
EP1053017B1 (en) 2004-09-08
CA2320041A1 (en) 1999-08-19
EP1053017A2 (en) 2000-11-22
IL137811A (en) 2005-12-18
DK1053017T3 (da) 2004-11-22
WO1999040938A3 (en) 2000-08-24
AU764036B2 (en) 2003-08-07
ES2226338T3 (es) 2005-03-16
DE69919984T2 (de) 2005-11-17
JP2002502884A (ja) 2002-01-29
AU2598199A (en) 1999-08-30
US6488936B1 (en) 2002-12-03
PT1053017E (pt) 2004-12-31
ATE275421T1 (de) 2004-09-15
KR20010040867A (ko) 2001-05-15
WO1999040938A2 (en) 1999-08-19
IL137811A0 (en) 2001-10-31
KR100622716B1 (ko) 2006-09-13
CN1224422C (zh) 2005-10-26

Similar Documents

Publication Publication Date Title
BR9907883A (pt) Composição de vacina, processo para eliciar uma resposta imune a um antìgeno de vìrus de herpes simplex, e, composição imunogênica
WO1999040936A3 (en) Pneumococcal and meningococcal vaccines formulated with interleukin-12
MX9702336A (es) Composiciones de vacuna.
AUPR011700A0 (en) Composition comprising immunogenic virus sized particles (VSP)
HK1022715A1 (en) Fusion proteins containing stress proteins for inducing immune responses
PT869814E (pt) Estabilizantes para vacinas vivas
BR9708387A (pt) Processo para vacinação de um mamìfero a um antìgeno selecionado, células patogênica e hospedeira, composição de vacina, ácido nucleico, e, opsonina engenheirada.
DE69929444D1 (de) Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
MX9401225A (es) Composicion de vacuna para prevenir la infeccion con influenza en humanos y metodo para su preparacion.
AU4622693A (en) Potentiation of immunogenic response
PT745388E (pt) Composicao de vacinas para mamiferos compreendendo esqualeno ou esqualano fosfolipido e um tensioactivo como adjevante
PT1047446E (pt) Composicao vacinica para o virus herpes simplex e metodos de utilizacao
BR0207528A (pt) Anticorpo, composição farmacêutica, e, usos de uma quantidade efetiva de um agente, de uma quantidade terapeuticamente efetiva de um anticorpo para il-22, de uma quantidade imunogênica do antìgeno e uma quantidade aumentadora de imunogenicidade de il-22 em combinação, de uma quantidade efetiva do anticorpo ou fragmento do mesmo e de uma quantidade suficiente de anticorpo ou fragmento ligado a antìgeno do mesmo
ATE319833T1 (de) Impfstoffe zur erhöhung der immunantworten gegen herpes simplex virus
ES2177535T3 (es) Vacunas contra protozoos intestinales.
AU1815899A (en) Method and composition to enhance the efficacy of a vaccine using chemokines
AP9901666A0 (en) Leishmania vaccine.
WO2005012538A3 (en) Accelerated vaccination
BR9912067A (pt) Composição liofilizada, composição de vacina composta e aquosa composta da composição liofilizada, composição de vacina, método de imunização de um vertebrado através de vacinação, método para a preparação de uma composição liofilizada e de uma suspensão coloidal aquosa
BR9709993A (pt) Vacina preparação de vacina composição processo para produção de uma preparação imugênica e preparação imugênica
DE60131975D1 (de) Anwendung des herpes simplex virus glykoproteins-d zur unterdrückung von immunantworten
BR9907885A (pt) Composição de vacina, processo para fazer surgir uma resposta imune a um antìgeno de vìrus sincicial respiratório, e, composição imunogênica
WO2001035993A3 (en) Compositions and methods for stimulating an immune response against infectious agents
ATE350058T1 (de) Sich gegenseitig schützende herpesviruszusammensetzung und verfahren zur deren herstellung und verwendung
EP1027895A3 (en) Erysipelothrix rhusiopathiae antigens and vaccine compositions

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B10A Cessation: cessation confirmed

Free format text: HOMOLOGADA A DESISTENCIA DO PEDIDO, SOLICITADA ATRAVES DA PETICAO NO 20090048590/RJ DE 20.05.2009.